Catalyst Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Catalyst Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-305,000	Closed	-$748K	–	523
2015 Q4	$748K	Hold	305,000	–	–	0.11%	139
2015 Q3	$915K	Sell	305,000 -1,005,000	-77%	-$4.34M	0.12%	149
2015 Q2	$5.41M	Buy	1,310,000 +235,000	+22%	+$937K	0.63%	68
2015 Q1	$4.66M	Buy	1,075,000 +120,000	+13%	+$433K	0.53%	79
2014 Q4	$2.84M	Hold	955,000	–	–	0.33%	77
2014 Q3	$3.17M	Buy	955,000 +125,000	+15%	+$327K	0.41%	75
2014 Q2	$2.1M	Buy	+830,000	New	+$1.77M	0.34%	91

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catalyst Capital Advisors's CPRX Position: Q1 2016 in Review

Catalyst Capital Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q1 2016, closing a stake of 305,000 shares — an estimated $748K sold.

Catalyst Capital Advisors first reported a position in CPRX in Q2 2014 and held it in 7 quarters. The position peaked at $5.41M in Q2 2015. 73 funds tracked by Wall St. Rank hold CPRX as of Q1 2016.

Catalyst Capital Advisors reported no remaining Catalyst Pharmaceutical position as of Q1 2016 after selling out during the quarter.
Catalyst Capital Advisors sold 305,000 Catalyst Pharmaceutical shares in Q1 2016, an estimated $748K.
Catalyst Capital Advisors first reported a position in Catalyst Pharmaceutical in Q2 2014 and held it in 7 quarters.
Catalyst Capital Advisors's Catalyst Pharmaceutical position peaked at $5.41M in Q2 2015.
73 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2016.

Based on Catalyst Capital Advisors's 13F filing for Q1 2016, filed 11 May 2016.